Charles River Laboratories International (NYSE:CRL) Price Target Raised to $190.00

by · The Markets Daily

Charles River Laboratories International (NYSE:CRL – Free Report) had its price target hoisted by JPMorgan Chase & Co. from $165.00 to $190.00 in a research note released on Monday,Benzinga reports. The firm currently has a neutral rating on the medical research company’s stock.

Other analysts also recently issued research reports about the stock. TD Cowen decreased their price objective on shares of Charles River Laboratories International from $205.00 to $197.00 and set a “buy” rating for the company in a research note on Monday, November 10th. Morgan Stanley set a $185.00 price target on Charles River Laboratories International in a report on Monday, December 1st. Robert W. Baird upgraded Charles River Laboratories International from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $178.00 to $199.00 in a report on Thursday, November 6th. Evercore ISI upped their price objective on Charles River Laboratories International from $190.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, October 3rd. Finally, Argus set a $200.00 target price on Charles River Laboratories International in a research note on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and a consensus target price of $194.07.

Check Out Our Latest Research Report on CRL

Charles River Laboratories International Stock Up 0.3%

NYSE CRL opened at $195.73 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. Charles River Laboratories International has a 52 week low of $91.86 and a 52 week high of $200.58. The firm has a market capitalization of $9.63 billion, a price-to-earnings ratio of -125.47, a PEG ratio of 6.90 and a beta of 1.63. The company has a fifty day moving average of $178.81 and a two-hundred day moving average of $164.72.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.11. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business’s revenue for the quarter was down .5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.59 earnings per share. On average, analysts predict that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRL. Nuveen LLC bought a new stake in shares of Charles River Laboratories International in the 1st quarter valued at about $18,538,000. Public Sector Pension Investment Board raised its stake in Charles River Laboratories International by 113.7% in the first quarter. Public Sector Pension Investment Board now owns 13,659 shares of the medical research company’s stock worth $2,056,000 after buying an additional 7,266 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Charles River Laboratories International by 30.0% during the first quarter. Dimensional Fund Advisors LP now owns 862,254 shares of the medical research company’s stock worth $129,799,000 after buying an additional 198,750 shares during the period. Ethic Inc. purchased a new stake in Charles River Laboratories International during the first quarter worth $523,000. Finally, American Century Companies Inc. boosted its position in Charles River Laboratories International by 29.1% during the 1st quarter. American Century Companies Inc. now owns 3,853 shares of the medical research company’s stock valued at $580,000 after acquiring an additional 869 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

(Get Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Further Reading